<p>3Chopt Investment Partners LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在百时美施贵宝公司（NYSE:BMY - 免费报告）的持股减少了 57.9%。该公司在季度内出售了 36,326 股后，持有 26,460 股该生物制药公司的股票。3Chopt Investment Partners LLC 在百时美施贵宝的持股在最近的报告期末价值为 1,193,000 美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<ul>
<li>为什么 GRAIL 股票可能成为生物技术的下一个重大突破</li>
</ul>
<p>其他机构投资者和对冲基金最近也对该公司的持股进行了调整。新英格兰资产管理公司在第一季度将其在百时美施贵宝的持股增加了 0.8%。新英格兰资产管理公司目前持有 39,476 股该生物制药公司的股票，价值 2,408,000 美元，此前在该期间内又增持了 305 股。英联邦退休投资公司在第二季度将其在百时美施贵宝的股份增加了 24.6%。英联邦退休投资公司目前持有 59,183 股该生物制药公司的股票，价值 2,740,000 美元，此前在该期间内又购买了 11,690 股。挪威银行在第二季度购买了百时美施贵宝的新股份，价值 1,554,154,000 美元。财富四分之一公司在第二季度将其在百时美施贵宝的股份增加了 42.6%。财富四分之一公司目前持有 25,443 股该生物制药公司的股票，价值 1,178,000 美元，此前在该期间内又增持了 7,603 股。最后，Sound View Wealth Advisors Group LLC 在第二季度将其在百时美施贵宝的持股增加了 438.0%。Sound View Wealth Advisors Group LLC 目前持有 307,849 股该生物制药公司的股票，价值 14,250,000 美元，此前在上个季度又增持了 250,624 股。机构投资者持有该公司 76.41% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>几位股票研究分析师对 BMY 股票发布了报告。高盛集团在 12 月 2 日的研究报告中重申了 “中性” 评级，并将百时美施贵宝的目标价上调至 57.00 美元（此前为 51.00 美元）。汇丰银行在 12 月 10 日的报告中重申了 “持有” 评级，并将百时美施贵宝的目标价设定为 53.00 美元。摩根士丹利在 12 月 12 日的报告中重申了 “减持” 评级，并将百时美施贵宝的目标价上调至 37.00 美元（此前为 36.00 美元）。古根海姆在 12 月 23 日的报告中重申了对百时美施贵宝的 “买入” 评级。最后，桑福德·C·伯恩斯坦在 11 月 3 日的研究报告中重申了对百时美施贵宝的 “市场表现” 评级。六位投资分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价为 54.62 美元。</p>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p><strong>阅读我们对百时美施贵宝的最新分析</strong></p>
<h2>百时美施贵宝股票上涨 0.2%</h2>
<p>NYSE:BMY 周三开盘价为 54.22 美元。该公司的流动比率为 1.27，速动比率为 1.17，债务与股本比率为 2.39。百时美施贵宝公司的 12 个月低点为 42.52 美元，12 个月高点为 63.33 美元。该公司的市值为 1,103.8 亿美元，市盈率为 18.32，市盈增长比率为 8.28，贝塔值为 0.29。该公司的 50 日移动平均线为 49.23 美元，200 日移动平均线为 47.39 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近一次发布季度财报是在 10 月 30 日，生物制药公司报告该季度每股收益为 1.63 美元，超出市场共识预期的 1.52 美元，超出幅度为 0.11 美元。百时美施贵宝的股本回报率为 76.53%，净利润率为 12.57%。该季度的营业收入为 122.2 亿美元，而市场共识预期为 117.5 亿美元。在去年同期，该公司的每股收益为 1.80 美元。该公司的季度收入较去年同期增长了 2.8%。百时美施贵宝已将其 2025 财年的指导目标设定为 6.400-6.600 美元每股收益。分析师预计百时美施贵宝公司今年将发布 6.74 美元的每股收益。</p>
<h2>百时美施贵宝增加股息</h2>
<p>该公司最近还披露了季度股息，将于 2 月 2 日（星期一）支付。1 月 2 日的股东将获得 0.63 美元的股息。除息日为 1 月 2 日。这比百时美施贵宝之前的季度股息 0.62 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 4.6%。百时美施贵宝的股息支付比率（DPR）目前为 83.78%。</p>
<h2>百时美施贵宝简介</h2>
<p>（免费报告）</p>
<p>百时美施贵宝是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。该公司的核心业务包括研究与开发、临床开发、制造和商业化多个治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
<p>BMS 的市场产品组合和后期管线反映出对癌症和免疫介导疾病的强烈关注。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>[毫无疑问的黄金投资]：“给我看看更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场察觉之前...而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

<p>3Chopt Investment Partners LLC 在第三季度将其在百时美施贵宝公司（NYSE:BMY）的持股减少了 57.9%，出售了 36,326 股，目前持有 26,460 股，市值为 119 万美元。其他机构投资者也调整了他们的持仓，新英格兰资产管理公司和联邦退休投资公司显著增加了持股。分析师对 BMY 的评级不一，平均目标价为 54.62 美元。该股票开盘价为 54.22 美元，略微上涨 0.2%。百时美施贵宝报告了强劲的季度收益，超出预期，每股收益为 1.63 美元，营收为 122.2 亿美元</p>

<p>3Chopt Investment Partners LLC cut its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 57.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,460 shares of the biopharmaceutical company's stock after selling 36,326 shares during the quarter. 3Chopt Investment Partners LLC's holdings in Bristol Myers Squibb were worth $1,193,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>3Chopt Investment Partners LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在百时美施贵宝公司（NYSE:BMY - 免费报告）的持股减少了 57.9%。该公司在季度内出售了 36,326 股后，持有 26,460 股该生物制药公司的股票。3Chopt Investment Partners LLC 在百时美施贵宝的持股在最近的报告期末价值为 1,193,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物技术的下一个重大突破</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. New England Asset Management Inc. boosted its holdings in Bristol Myers Squibb by 0.8% during the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock valued at $2,408,000 after acquiring an additional 305 shares during the period. Commonwealth Retirement Investments LLC increased its stake in Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company's stock worth $2,740,000 after purchasing an additional 11,690 shares during the period. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the second quarter worth $1,554,154,000. Wealth Quarterback LLC boosted its stake in shares of Bristol Myers Squibb by 42.6% during the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company's stock valued at $1,178,000 after purchasing an additional 7,603 shares during the period. Finally, Sound View Wealth Advisors Group LLC grew its holdings in shares of Bristol Myers Squibb by 438.0% in the second quarter. Sound View Wealth Advisors Group LLC now owns 307,849 shares of the biopharmaceutical company's stock worth $14,250,000 after purchasing an additional 250,624 shares during the last quarter. Institutional investors own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也对该公司的持股进行了调整。新英格兰资产管理公司在第一季度将其在百时美施贵宝的持股增加了 0.8%。新英格兰资产管理公司目前持有 39,476 股该生物制药公司的股票，价值 2,408,000 美元，此前在该期间内又增持了 305 股。英联邦退休投资公司在第二季度将其在百时美施贵宝的股份增加了 24.6%。英联邦退休投资公司目前持有 59,183 股该生物制药公司的股票，价值 2,740,000 美元，此前在该期间内又购买了 11,690 股。挪威银行在第二季度购买了百时美施贵宝的新股份，价值 1,554,154,000 美元。财富四分之一公司在第二季度将其在百时美施贵宝的股份增加了 42.6%。财富四分之一公司目前持有 25,443 股该生物制药公司的股票，价值 1,178,000 美元，此前在该期间内又增持了 7,603 股。最后，Sound View Wealth Advisors Group LLC 在第二季度将其在百时美施贵宝的持股增加了 438.0%。Sound View Wealth Advisors Group LLC 目前持有 307,849 股该生物制药公司的股票，价值 14,250,000 美元，此前在上个季度又增持了 250,624 股。机构投资者持有该公司 76.41% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several equities research analysts have issued reports on BMY shares. The Goldman Sachs Group reissued a &#34;neutral&#34; rating and issued a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. HSBC reiterated a &#34;hold&#34; rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Morgan Stanley restated an &#34;underweight&#34; rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Guggenheim reiterated a &#34;buy&#34; rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. Finally, Sanford C. Bernstein reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Six investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $54.62.</p>
<div class="lb-trans"><p>几位股票研究分析师对 BMY 股票发布了报告。高盛集团在 12 月 2 日的研究报告中重申了 “中性” 评级，并将百时美施贵宝的目标价上调至 57.00 美元（此前为 51.00 美元）。汇丰银行在 12 月 10 日的报告中重申了 “持有” 评级，并将百时美施贵宝的目标价设定为 53.00 美元。摩根士丹利在 12 月 12 日的报告中重申了 “减持” 评级，并将百时美施贵宝的目标价上调至 37.00 美元（此前为 36.00 美元）。古根海姆在 12 月 23 日的报告中重申了对百时美施贵宝的 “买入” 评级。最后，桑福德·C·伯恩斯坦在 11 月 3 日的研究报告中重申了对百时美施贵宝的 “市场表现” 评级。六位投资分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价为 54.62 美元。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>阅读我们对百时美施贵宝的最新分析</strong></p>
</div><h2>Bristol Myers Squibb Stock Up 0.2%</h2>
<div class="lb-trans"><h2>百时美施贵宝股票上涨 0.2%</h2>
</div><p>NYSE:BMY opened at $54.22 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a market cap of $110.38 billion, a PE ratio of 18.32, a P/E/G ratio of 8.28 and a beta of 0.29. The company's 50 day moving average is $49.23 and its two-hundred day moving average is $47.39.</p>
<div class="lb-trans"><p>NYSE:BMY 周三开盘价为 54.22 美元。该公司的流动比率为 1.27，速动比率为 1.17，债务与股本比率为 2.39。百时美施贵宝公司的 12 个月低点为 42.52 美元，12 个月高点为 63.33 美元。该公司的市值为 1,103.8 亿美元，市盈率为 18.32，市盈增长比率为 8.28，贝塔值为 0.29。该公司的 50 日移动平均线为 49.23 美元，200 日移动平均线为 47.39 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same quarter in the previous year, the business earned $1.80 EPS. The company's quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近一次发布季度财报是在 10 月 30 日，生物制药公司报告该季度每股收益为 1.63 美元，超出市场共识预期的 1.52 美元，超出幅度为 0.11 美元。百时美施贵宝的股本回报率为 76.53%，净利润率为 12.57%。该季度的营业收入为 122.2 亿美元，而市场共识预期为 117.5 亿美元。在去年同期，该公司的每股收益为 1.80 美元。该公司的季度收入较去年同期增长了 2.8%。百时美施贵宝已将其 2025 财年的指导目标设定为 6.400-6.600 美元每股收益。分析师预计百时美施贵宝公司今年将发布 6.74 美元的每股收益。</p>
</div><h2>Bristol Myers Squibb Increases Dividend</h2>
<div class="lb-trans"><h2>百时美施贵宝增加股息</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This is an increase from Bristol Myers Squibb's previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 83.78%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 2 月 2 日（星期一）支付。1 月 2 日的股东将获得 0.63 美元的股息。除息日为 1 月 2 日。这比百时美施贵宝之前的季度股息 0.62 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 4.6%。百时美施贵宝的股息支付比率（DPR）目前为 83.78%。</p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百时美施贵宝简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百时美施贵宝是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。该公司的核心业务包括研究与开发、临床开发、制造和商业化多个治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市场产品组合和后期管线反映出对癌症和免疫介导疾病的强烈关注。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>[毫无疑问的黄金投资]：“给我看看更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场察觉之前...而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

3Chopt Investment Partners LLC 出售了 36,326 股百时美施贵宝公司（Bristol Myers Squibb）的股票$BMY